Preclinical Efficacy of Anecortave Acetate

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.

Original languageEnglish
Pages (from-to)S41-S48
JournalSurvey of Ophthalmology
Issue number1 SUPPL.
StatePublished - 1 Jan 2007


  • age-related macular degeneration
  • anecortave acetate
  • choroidal neovascularization
  • efficacy
  • preclinical


Dive into the research topics of 'Preclinical Efficacy of Anecortave Acetate'. Together they form a unique fingerprint.

Cite this